1100 related articles for article (PubMed ID: 30796368)
1. Liquid biopsy and minimal residual disease - latest advances and implications for cure.
Pantel K; Alix-Panabières C
Nat Rev Clin Oncol; 2019 Jul; 16(7):409-424. PubMed ID: 30796368
[TBL] [Abstract][Full Text] [Related]
2. Liquid Biopsy for the Management of Patients with Colorectal Cancer.
Yamada T; Matsuda A; Koizumi M; Shinji S; Takahashi G; Iwai T; Takeda K; Ueda K; Yokoyama Y; Hara K; Hotta M; Matsumoto S; Yoshida H
Digestion; 2019; 99(1):39-45. PubMed ID: 30554222
[TBL] [Abstract][Full Text] [Related]
3. Liquid biopsy in breast cancer: A comprehensive review.
Alimirzaie S; Bagherzadeh M; Akbari MR
Clin Genet; 2019 Jun; 95(6):643-660. PubMed ID: 30671931
[TBL] [Abstract][Full Text] [Related]
4. Cell-Free DNA in the Liquid Biopsy Context: Role and Differences Between ctDNA and CTC Marker in Cancer Management.
Fici P
Methods Mol Biol; 2019; 1909():47-73. PubMed ID: 30580422
[TBL] [Abstract][Full Text] [Related]
5. Liquid biopsy and its role in an advanced clinical trial for lung cancer.
Johann DJ; Steliga M; Shin IJ; Yoon D; Arnaoutakis K; Hutchins L; Liu M; Liem J; Walker K; Pereira A; Yang M; Jeffus SK; Peterson E; Xu J
Exp Biol Med (Maywood); 2018 Feb; 243(3):262-271. PubMed ID: 29405770
[TBL] [Abstract][Full Text] [Related]
6. Minimal residual disease in breast cancer: an overview of circulating and disseminated tumour cells.
Tachtsidis A; McInnes LM; Jacobsen N; Thompson EW; Saunders CM
Clin Exp Metastasis; 2016 Aug; 33(6):521-50. PubMed ID: 27189371
[TBL] [Abstract][Full Text] [Related]
7. [Liquid biopsy in colorectal cancer : An overview of ctDNA analysis in tumour diagnostics].
Haupts A; Roth W; Hartmann N
Pathologe; 2019 Dec; 40(Suppl 3):244-251. PubMed ID: 31797045
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive liquid biopsy analysis as a tool for the early detection of minimal residual disease in breast cancer.
Stergiopoulou D; Markou A; Strati A; Zavridou M; Tzanikou E; Mastoraki S; Kallergi G; Georgoulias V; Lianidou E
Sci Rep; 2023 Jan; 13(1):1258. PubMed ID: 36690653
[TBL] [Abstract][Full Text] [Related]
9. Detecting liquid remnants of solid tumors treated with curative intent: Circulating tumor DNA as a biomarker of minimal residual disease (Review).
Chen H; Zhou Q
Oncol Rep; 2023 May; 49(5):. PubMed ID: 37052271
[TBL] [Abstract][Full Text] [Related]
10. The potential of liquid biopsy in the management of cancer patients.
Markou A; Tzanikou E; Lianidou E
Semin Cancer Biol; 2022 Sep; 84():69-79. PubMed ID: 35331850
[TBL] [Abstract][Full Text] [Related]
11. Liquid biopsy: novel technologies and clinical applications.
Reimers N; Pantel K
Clin Chem Lab Med; 2019 Feb; 57(3):312-316. PubMed ID: 30465714
[TBL] [Abstract][Full Text] [Related]
12. Current and future applications of liquid biopsy in nonsmall cell lung cancer from early to advanced stages.
Guibert N; Pradines A; Favre G; Mazieres J
Eur Respir Rev; 2020 Mar; 29(155):. PubMed ID: 32051167
[TBL] [Abstract][Full Text] [Related]
13. Liquid biopsy and their application progress in head and neck cancer: focus on biomarkers CTCs, cfDNA, ctDNA and EVs.
Meng Y; Bian L; Zhang M; Bo F; Lu X; Li D
Biomark Med; 2020 Oct; 14(14):1393-1404. PubMed ID: 33073579
[TBL] [Abstract][Full Text] [Related]
14. Advances in liquid biopsy using circulating tumor cells and circulating cell-free tumor DNA for detection and monitoring of breast cancer.
Zhang X; Ju S; Wang X; Cong H
Clin Exp Med; 2019 Aug; 19(3):271-279. PubMed ID: 31190187
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers of minimal residual disease and treatment.
Murray NP
Adv Clin Chem; 2024; 119():33-70. PubMed ID: 38514211
[TBL] [Abstract][Full Text] [Related]
16. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy.
Alix-Panabières C; Pantel K
Cancer Discov; 2016 May; 6(5):479-91. PubMed ID: 26969689
[TBL] [Abstract][Full Text] [Related]
17. Cell-free DNA in cancer: current insights.
Fettke H; Kwan EM; Azad AA
Cell Oncol (Dordr); 2019 Feb; 42(1):13-28. PubMed ID: 30367445
[TBL] [Abstract][Full Text] [Related]
18. Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis.
Zhong R; Gao R; Fu W; Li C; Huo Z; Gao Y; Lu Y; Li F; Ge F; Tu H; You Z; He J; Liang W
BMC Med; 2023 May; 21(1):180. PubMed ID: 37173789
[TBL] [Abstract][Full Text] [Related]
19. Application of liquid biopsy in precision medicine: opportunities and challenges.
Wang J; Chang S; Li G; Sun Y
Front Med; 2017 Dec; 11(4):522-527. PubMed ID: 28744793
[TBL] [Abstract][Full Text] [Related]
20. The relevance of liquid biopsy in surgical oncology: The application of perioperative circulating nucleic acid dynamics in improving patient outcomes.
Jordan PR; O'Leary DP; Fleming CA; Wang J; Redmond HP
Surgeon; 2022 Aug; 20(4):e163-e173. PubMed ID: 34362650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
